Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology - Symphogen’s strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers.
Location: Denmark, Capital Region of Denmark, Måløv
Employees: 51-200
Total raised: $431.7M
Founded date: 2000
Investors 2
| Date | Name | Website |
| 14.05.2021 | EW Healthc... | ewhealthca... |
| - | Gilde Heal... | gildehealt... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 22.10.2015 | - | $74.97M | - |
| 02.05.2013 | - | $184.04M | - |
| 06.01.2011 | - | $130.29M | - |
| 04.02.2009 | - | $42.4M | - |
Mentions in press and media 10
| Date | Title | Description |
| 18.08.2016 | Essex Woodlands Health Ventures-backed Symphogen CEO Kirsten Drejer to Step Down | COPENHAGEN, Denmark–(BUSINESS WIRE)–Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Kirsten Drejer, M.Sc., Ph. D., Co-founder, Chief Executive Officer and Director will transitio... |
| 23.10.2015 | Symphogen Closes €67.5M Convertible Debt Facility | Symphogen, a Copenhagen, Denmark-based biopharmaceutical company developing recombinant antibody mixtures, closed a €67.5m convertible debt facility from existing investors. The round, which brought total pro-forma cash resources to a total... |
| 22.10.2015 | Symphogen Announces Closing of a EUR 67.5 M Financing Subscribed by Existing Investors | Copenhagen, Denmark – Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the closing of a EUR 67.5 million convertible debt facility, secured from existing investors, led by Novo A... |
| 21.04.2015 | EUSA Pharma Appoints Lee Morley Chief Executive & Industry Veteran Goran Ando to Board of Directors | Apr 21 2015 HEMEL HEMPSTEAD, United Kingdom – – EUSA Pharma (EUSA), a recently-established profitable specialty pharmaceutical company with global reach, today announced the appointment of Lee Morley as Chief Executive Officer, and Dr Göra... |
| 03.05.2013 | Symphogen Closes Additional €41M Financing | Symphogen, a Copenhagen, Denmark-based biopharmaceutical company developing recombinant antibody mixtures, closed an additional €41m financing. Backers included Novo A/S and PKA with investments of €20 million each, and Danica Pension... |
| 02.05.2013 | Symphogen Expands Previous Private Equity Round, Reaching a Total of €141 million (USD 185 million) | Copenhagen, Denmark – Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it closed an expansion of its previously announced €100 million financing attaining a total of a €141 ... |
| 02.04.2012 | Symphogen Receives Second Tranche of €100m Financing | Symphogen, a Copenhagen, Denmark-based developer of antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal), received the second of three tranches of capital specified in its €100 million 2011 financing (read here). The round... |
| 06.01.2011 | Symphogen Closes €100M Round of Financing | Symphogen, a Copenhagen, Denmark-based biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, closed a €100m round of financing. The round was led Novo A/S with participation... |
| 06.01.2011 | Symphogen Raises EUR 100 Million, The Largest Private Round In European Biotech Ever | UTRECHT, Netherlands – Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced that it closed a... |
| 04.02.2009 | SYMPHOGEN Secures EUR 33 million Financing to Support Clinical Development of Antibody Products | COPENHAGEN, Denmark - Symphogen A/S today announced the closing of a € 33 million (approximately U.S. $44 million) financing. Existing investors participated in the round, which was led by Essex Woodlands Health Ventures. The financing will... |